{"transactions":[{"id":1016384,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-17T18:01:00.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":20272,"price":7,"value":141904.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported transaction involves sale transactions from $7.00 to $7.02 per share. The weighted average price per share was $7.00. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price."}],"balance_after":282475,"source":{"system":"sec-edgar","filing":"0001214659-25-015047","document":"marketforms-71050.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465925015047/marketforms-71050.xml","form_type":"4"}},{"id":1068628,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-12T14:11:01.000Z","date":"2025-08-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":10819,"price":3.9,"value":42194.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units (\"RSUs\") previously granted to the Reporting Person."}],"balance_after":302747,"source":{"system":"sec-edgar","filing":"0001214659-25-011823","document":"marketforms-70221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465925011823/marketforms-70221.xml","form_type":"4"}},{"id":1211724,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-03-11T21:48:34.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment."}],"balance_after":30000,"derivative":{"exercise_price":2.65,"expiration_date":"2035-03-07","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001214659-25-004225","document":"marketforms-68573.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465925004225/marketforms-68573.xml","form_type":"4"}},{"id":1211723,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-11T21:48:34.000Z","date":"2025-03-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":8115,"price":2.65,"value":21504.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units (\"RSUs\") previously granted to the Reporting Person."}],"balance_after":313566,"source":{"system":"sec-edgar","filing":"0001214659-25-004225","document":"marketforms-68573.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465925004225/marketforms-68573.xml","form_type":"4"}},{"id":1211722,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-11T21:48:34.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment"}],"balance_after":321681,"source":{"system":"sec-edgar","filing":"0001214659-25-004225","document":"marketforms-68573.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465925004225/marketforms-68573.xml","form_type":"4"}},{"id":1435790,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-12T18:45:02.000Z","date":"2024-08-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":10819,"price":3.43,"value":37109.17,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units (\"RSUs\") previously granted to the Reporting Person."}],"balance_after":251681,"source":{"system":"sec-edgar","filing":"0001214659-24-014226","document":"marketforms-66654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465924014226/marketforms-66654.xml","form_type":"4"}},{"id":1583732,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-11T14:35:52.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment."}],"balance_after":56250,"derivative":{"exercise_price":5.68,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001214659-24-004306","document":"marketforms-64692.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465924004306/marketforms-64692.xml","form_type":"4"}},{"id":1583731,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-11T14:35:52.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment"}],"balance_after":262500,"source":{"system":"sec-edgar","filing":"0001214659-24-004306","document":"marketforms-64692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465924004306/marketforms-64692.xml","form_type":"4"}},{"id":1811759,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-09T20:30:31.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment"}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001214659-23-010919","document":"marketforms-62126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465923010919/marketforms-62126.xml","form_type":"4"}},{"id":2037281,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Options (Right ot Buy)","published_at":"2023-02-02T20:10:55.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":25400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer."}],"balance_after":25400,"derivative":{"exercise_price":5.21,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":25400},"source":{"system":"sec-edgar","filing":"0001415889-23-001856","document":"form4-02032023_010245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000141588923001856/form4-02032023_010245.xml","form_type":"4"}},{"id":2051624,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Options (Right to Buy)","published_at":"2023-01-19T21:46:11.000Z","date":"2023-01-17","kind":"exercise","acquired":true,"shares":440844,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (\"Series Z Preferred Stock\") converted into shares of common stock of the Issuer, par value $0.001 per share (\"Common Stock\"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time."}],"balance_after":440844,"derivative":{"exercise_price":208.76,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":440844},"source":{"system":"sec-edgar","filing":"0001104659-23-005134","document":"tm233989-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465923005134/tm233989-2_4seq1.xml","form_type":"4"}},{"id":2149044,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series Z Preferred Stock","published_at":"2022-09-30T21:48:39.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":6843,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is\nconvertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations (represents Series Z Preferred Stock\noptions issuable upon the exercise of the Series Z Stock options reported above)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28,\n2022 (the \"Merger Agreement\"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Shares of Aceragen common stock\nconvertible into shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and shares of the Idera Series Z Non-Voting Convertible\nPreferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28,\n2022 (the \"Merger Agreement\"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Shares of Aceragen common stock\nconvertible into shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and shares of the Idera Series Z Non-Voting Convertible\nPreferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is\nconvertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations (represents Series Z Preferred Stock\noptions issuable upon the exercise of the Series Z Stock options reported above)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is\nconvertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations (represents Series Z Preferred Stock\noptions issuable upon the exercise of the Series Z Stock options reported above)."}],"balance_after":6843,"derivative":{"underlying":"Common Stock","underlying_shares":6843000},"source":{"system":"sec-edgar","filing":"0001104659-22-104795","document":"tm2227191-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465922104795/tm2227191-7_4seq1.xml","form_type":"4"}},{"id":2149043,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Options (Right to Buy)","published_at":"2022-09-30T21:48:39.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":6843,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28,\n2022 (the \"Merger Agreement\"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Shares of Aceragen common stock\nconvertible into shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and shares of the Idera Series Z Non-Voting Convertible\nPreferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the Reporting Person received Idera options for 651,364 shares of Common Stock and options for 6,843 shares of Series Z\nPreferred Stock options in exchange for 300,000 Aceragen options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued\nservice to Issuer through each vesting date."}],"balance_after":6843,"derivative":{"exercise_price":12280,"expiration_date":"2032-02-09","underlying":"Series Z Preferred Stock","underlying_shares":6843},"source":{"system":"sec-edgar","filing":"0001104659-22-104795","document":"tm2227191-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465922104795/tm2227191-7_4seq1.xml","form_type":"4"}},{"id":2149042,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":74153,"kind":"person","name":"Kraus Carl N","position":1,"cik":"0001946475","reported_name":"Kraus Carl N","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Options (Right to Buy)","published_at":"2022-09-30T21:48:39.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":651364,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. (\"Idera\") and Aceragen, Inc. (\"Aceragen\"), dated September 28,\n2022 (the \"Merger Agreement\"), Aceragen merged with and became a wholly-owned subsidiary of Idera (the \"Merger\"). Shares of Aceragen common stock\nconvertible into shares of common stock of Idera, par value $0.001 per share (\"Common Stock\") and shares of the Idera Series Z Non-Voting Convertible\nPreferred Stock, par value $0.01 (\"Series Z Preferred Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the Reporting Person received Idera options for 651,364 shares of Common Stock and options for 6,843 shares of Series Z\nPreferred Stock options in exchange for 300,000 Aceragen options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued\nservice to Issuer through each vesting date."}],"balance_after":651364,"derivative":{"exercise_price":12.28,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":651364},"source":{"system":"sec-edgar","filing":"0001104659-22-104795","document":"tm2227191-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000110465922104795/tm2227191-7_4seq1.xml","form_type":"4"}}]}